DEA Places Sedative Into Schedule IV

The Drug Enforcement Administration is placing the newly approved drug remimazolam in Schedule V of the Controlled Substances Act, it said in an interim final rule. Effective Oct. 6, remimazolam, which was granted approval by the Food and Drug Administration in June, is subject to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until Nov. 5.